Trial · NCT06313996
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 5 years from the last participant randomized | Defined as the time from randomization to death due to any cause or progressive disease (PD) per independent review committee (IRC) assessment using the Lugano 2014 Criteria, whichever occurs first |
| Secondary | Complete response (CR) | Up to 5 years from the last participant randomized | Defined as participants achieving a complete response per IRC assessment using the Lugano 2014 Criteria |
| Secondary | Overall survival (OS) | Up to approximately 7 years | Defined as the time from randomization to death due to any cause |
| Secondary | Overall response (OR) | Up to 5 years from the last participant randomized | Defined as participants achieving a response (CR or partial response (PR)) per IRC assessment using the Lugano 2014 Criteria |
| Secondary | Duration of response (DOR) | Up to 5 years from the last participant randomized | Defined as the time from first response (CR or PR) per IRC assessment using the Lugano 2014 Criteria to PD or death due to any cause, whichever occurs first |
| Secondary | Event-free survival (EFS) | Up to 5 years from the last participant randomized | Defined as the time from randomization to the first documentation of progressive disease (PD) per IRC assessed using the Lugano 2014 Criteria start of new anti-cancer therapy, or death due to any cause, whichever occurs first |
| Secondary | Time to next anti-cancer therapy (TTNLT) | Up to 5 years from the last participant randomized | Defined as time from randomization to start of new anti-cancer therapy or death due to any cause, whichever occurs first |
| Secondary | PFS rate | Up to 5 years from the last participant randomized | |
| Secondary | EFS rate | Up to 5 years from the last participant randomized | |
| Secondary | OS rate | Up to approximately 7 years | |
| Secondary | Progression-free survival on the next line of treatment (PFS-2) | Up to 5 years from the last participant randomized | Defined as the time from randomization to death from any cause or tumor progression on next line treatment per Investigator assessment, whichever occurs first |
| Secondary | Number of participants with adverse events (AEs) | Up to 5 years from the last participant randomized | |
| Secondary | Number of participants with adverse event of special interest (AESIs) | Up to 5 years from the last participant randomized | |
| Secondary | Number of participants with serious adverse events (SAEs) | Up to 5 years from the last participant randomized | |
| Secondary | Number of participants with laboratory abnormalities | Up to 5 years from the last participant randomized | |
| Secondary | Frequency and length of hospitalizations | Up to 5 years from the last participant randomized | |
| Secondary | Number of participants with intensive care unit (ICU) inpatient days | Up to 5 years from the last participant randomized | |
| Secondary | Number of participants with non-ICU inpatient days | Up to 5 years from the last participant randomized | |
| Secondary | Mean change from baseline in key health-related quality of life (HRQoL) domains. | Up to 5 years from the last participant randomized | Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20) |
| Secondary | Time to meaningful improvement/deterioration in key HRQoL domains. | Up to 5 years from the last participant randomized | Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06313996/registered